Developer docs
API playgroundTry for free, no card

Search company profiles

evitria

Full company profile

uuid000gdd4

Namestring
evitria
Legal namestring
evitria AG
Websiteurl
evitria.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

evitria AG is a privately held contract research organization founded in 2010 and headquartered in Zurich-Fahrweid, Switzerland. The company provides custom recombinant antibody and protein production services using a Chinese Hamster Ovary (CHO) cell-based transient expression platform, serving biotech, biopharmaceutical, academic and government research customers across North America, Europe and Asia-Pacific. Its service portfolio covers six core offerings — standard recombinant IgG production, bispecific antibodies, afucosylated (ADCC-enhanced) antibodies, Fc-silenced antibodies, high-throughput parallel expression, and non-antibody recombinant proteins — delivered with a standard 4-week turnaround, >95% purity on bispecific formats, and endotoxin levels below 1 EU/mg.

The technical differentiation rests on a stack of licensed proprietary platforms: GlymaxX® from ProBioGen for glycoengineering and fucose modulation, Opti-mAb® from AAX Biotech for scFv stabilization in bispecific formats, STR (True Fc Silencing) from mAbsolve for Fc-null antibodies, and bYlok® from Lonza for correct heavy- and light-chain pairing in IgG-like bispecifics. Since founding, evitria has executed over 140,000 transfections and delivered more than 25,000 antibodies, reflecting 15 years of accumulated CHO process know-how.

Commercially, evitria operates a B2B professional services model with quote-based, pay-as-you-go project pricing determined by antibody format, scale, timeline and quality requirements. Distribution is direct via the company website, email contact, and regional business development managers (e.g., Manchester/Great Britain coverage by Brad Gartland), supported by industry conference participation and an educational Antibody Journal content marketing program. Revenue is generated entirely from custom antibody and protein production service fees; no platform licensing, milestone, or royalty streams are disclosed.

Short descriptiontext

evitria is a Zurich-based contract research organization providing custom recombinant antibody and protein production services in CHO cells for biotech and pharmaceutical companies globally, with a 4-week standard turnaround and licensed technology platforms for bispecific, afucosylated, and Fc-silenced formats.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersZürich, Switzerland
HQ citystring
Zürich
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
recombinant antibody production, CHO cell expression services, bispecific antibody manufacturing, therapeutic antibody development, antibody expression CRO
Industry2 codes
PRIMARYHLAMANAE
Exosome & Extracellular Vesicle (EV) Therapeutics
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
Product category
Contract Antibody Production Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Custom Antibody Expression Services
TypeProfessional Services
Description

evitria provides custom recombinant antibody production services in CHO cells, generating revenue through project-based fees. Services include recombinant IgG production, bispecific antibodies, afucosylated antibodies, Fc-silenced antibodies, high-throughput production, and other recombinant proteins. Pricing is quote-based and depends on antibody format, production scale, timeline, and quality requirements.

evitria.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Quote-based pricing tailored to project requirements
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing depends on antibody format, production scale, timeline and quality requirements. evitria provides a tailored quote within a few working days after project scope discussion.

evitria.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

evitria is a CRO providing custom recombinant antibody production services using an optimized CHO (Chinese Hamster Ovary) cell-based transient expression platform. Services span standard IgG production, bispecific and multispecific antibody formats, afucosylated (ADCC-enhanced) antibodies, Fc-silenced antibodies, high-throughput parallel expression, and other recombinant proteins, with a 4-week standard turnaround from sequence to purified protein.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 140,000+ transfections and 25,000+ antibodies delivered since 2010
+5 more records
Product overview1 text field

evitria is a contract research organization (CRO) providing custom antibody production services using an optimized CHO cell expression platform. The company's portfolio includes six distinct service offerings: Recombinant Antibody Expression Service (standard IgG production), Bispecific Antibody Production Service (dual-targeting formats), Afucosylated Antibody Expression Service (ADCC-enhanced via GlymaxX®), Fc-Silenced Antibody Production Service (reduced effector function via STR technology), High-Throughput Antibody Production Service (parallel expression of hundreds of constructs), and Recombinant Protein Expression Service (non-antibody proteins). These services are powered by three licensed technology platforms: GlymaxX® for glycoengineering, Opti-mAb® for scFv stabilization, and STR for true Fc silencing. All production uses mammalian (CHO) cell-based transient expression with a 4-week standard turnaround.

Product and service6 records
1Recombinant Antibody Expression Service
CategoryAntibody Production Services
Description

Custom production of recombinant monoclonal antibodies in CHO cells, delivering purified proteins from antibody sequences in as little as 4 weeks, with low endotoxin levels (<1 EU/mg). Standard IgG production for biotech and pharma therapeutic programs.

2Bispecific Antibody Production Service
CategoryAntibody Production Services
Description

Production of bispecific antibodies capable of simultaneously binding to two different antigens or epitopes. Uses bYlok® technology from Lonza to address heavy-light chain mispairing challenges, with >95% purity achievable.

3Afucosylated Antibody Expression Service
CategoryAntibody Production Services
Description

Production of afucosylated antibodies lacking fucose residues in the Fc region, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) for increased therapeutic potency in oncology applications. Uses GlymaxX® glycoengineering technology.

4Fc-Silenced Antibody Production Service
CategoryAntibody Production Services
Description

Production of antibodies with reduced or eliminated Fc effector functions using STR (True Fc Silencing) technology from mAbsolve, ideal for neutralizing interactions without triggering immune responses.

5High-Throughput Antibody Production Service
CategoryAntibody Production Services
Description

Parallel expression of up to several hundred antibody constructs per project, delivering purified, assay-ready material in as little as 4 weeks with >95% purity. Designed for AI-driven antibody discovery and optimization pipelines.

6Recombinant Protein Expression Service
CategoryRecombinant Protein Production Services
Description

Production of non-antibody soluble proteins including antigens, extracellular domains, cytokines, viral proteins, and alternative scaffolds using the CHO cell expression platform.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-01
Description

Partnership to enable use of Opti-mAb® technology in early antibody development workflows. AAX Biotech develops proprietary technologies including Opti-mAb® supporting antibody-based therapies. The partnership expands access to scFv stabilization technology for bispecific antibody development.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-05-01
Description

Non-exclusive license agreement for bYlok® technology enabling simple and reliable development of IgG-like bispecific antibodies. Addresses the challenge of correct heavy chain and light chain pairing in bispecific antibody generation for discovery-stage transient expression research.

Strategic tierCoreTypeTechnology or Integration
Description

Exclusive licensing partnership for GlymaxX® technology enabling modulation of fucosylation in CHO cells. The technology uses a deflecting enzyme to deplete fucose monosaccharides from glycosylation pathways, allowing fine-tuning from complete lack to fully fucosylated variants. Critical for producing ADCC-enhanced afucosylated antibodies.

Strategic tierMinorTypeOthers
Description

Listed as a partnership on evitria's partnerships page. Nature of partnership not detailed in available sources.

Strategic tierMinorTypeOthers
Description

Listed as a partnership on evitria's HTML sitemap. Nature of partnership not detailed in available sources.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global CDMO offering end-to-end biologics services including mammalian cell expression, stable cell line development, and GMP manufacturing. Direct comparability on transient and stable CHO expression; Lonza also licenses bYlok® to evitria, making it both a partner and broader incumbent.

TypeBroad incumbent
Description

Global CRO/CDMO with extensive biologics and antibody discovery services. Comparable through its Antibody Discovery & Optimization offerings; Brad Gartland (evitria's BDM) previously held senior commercial roles at Charles River, highlighting operational overlap.

TypeDirect peer
Description

Provides custom antibody and protein production services using mammalian (HEK/CHO) expression, including recombinant antibody expression, bispecific antibody production, and high-throughput formats. Directly competes with evitria on CHO-based transient expression for biotech and pharma customers.

TypeDirect peer
Description

Berlin-based CDMO specializing in mammalian cell engineering, cell line development, and viral vectors. Also licenses its GlymaxX® technology to evitria, making it both a core technology partner and a peer offering CHO-based expression services with proprietary glycoengineering capabilities.

5Absolute Antibody
TypeDirect peer
Description

Recombinant antibody production and engineering services including antibody reformatting, Fc-engineering, and custom expression. Comparable to evitria on recombinant mAb and Fc-engineered antibody services for therapeutic and research customers.

TypeDirect peer
Description

Recombinant antibody and protein production CRO with HEK293 and CHO cell expression, including bispecific and Fc-engineered formats. Directly comparable service portfolio serving global biotech and pharma with custom antibody expression.

TypeDirect peer
Description

Custom antibody services including recombinant antibody production, antibody engineering, bispecific antibody development, and Fc-silencing. Direct competitor to evitria across the full antibody expression service stack.

TypeBroad incumbent
Description

Global biologics CDMO offering discovery through GMP manufacturing with extensive mammalian cell expression capacity. Comparable on CHO-based transient and stable expression but at much larger scale across the value chain.

TypeBroad incumbent
Description

Global CDMO with biologics capabilities including mammalian cell line development and biopharmaceutical manufacturing. Comparable in the broader biologics services space, particularly for customers needing integrated discovery-to-GMP workflows.

TypeEmerging player
Description

Developer of the STR (True Fc Silencing) technology that evitria licenses. A focused emerging player in Fc-silenced antibody tools, providing complementary technology and direct partnership/peer dynamics with evitria.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

evitria

Contract Antibody Production Servicesevitria.com

evitria is a Zurich-based contract research organization providing custom recombinant antibody and protein production services in CHO cells for biotech and pharmaceutical companies globally, with a 4-week standard turnaround and licensed technology platforms for bispecific, afucosylated, and Fc-silenced formats.

What evitria does

evitria AG is a privately held contract research organization founded in 2010 and headquartered in Zurich-Fahrweid, Switzerland. The company provides custom recombinant antibody and protein production services using a Chinese Hamster Ovary (CHO) cell-based transient expression platform, serving biotech, biopharmaceutical, academic and government research customers across North America, Europe and Asia-Pacific. Its service portfolio covers six core offerings — standard recombinant IgG production, bispecific antibodies, afucosylated (ADCC-enhanced) antibodies, Fc-silenced antibodies, high-throughput parallel expression, and non-antibody recombinant proteins — delivered with a standard 4-week turnaround, >95% purity on bispecific formats, and endotoxin levels below 1 EU/mg.

The technical differentiation rests on a stack of licensed proprietary platforms: GlymaxX® from ProBioGen for glycoengineering and fucose modulation, Opti-mAb® from AAX Biotech for scFv stabilization in bispecific formats, STR (True Fc Silencing) from mAbsolve for Fc-null antibodies, and bYlok® from Lonza for correct heavy- and light-chain pairing in IgG-like bispecifics. Since founding, evitria has executed over 140,000 transfections and delivered more than 25,000 antibodies, reflecting 15 years of accumulated CHO process know-how.

Commercially, evitria operates a B2B professional services model with quote-based, pay-as-you-go project pricing determined by antibody format, scale, timeline and quality requirements. Distribution is direct via the company website, email contact, and regional business development managers (e.g., Manchester/Great Britain coverage by Brad Gartland), supported by industry conference participation and an educational Antibody Journal content marketing program. Revenue is generated entirely from custom antibody and protein production service fees; no platform licensing, milestone, or royalty streams are disclosed.

evitria firmographics

Firmographics
Name
evitria
Legal name
evitria AG
Website
https://evitria.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
evitria is a Zurich-based contract research organization providing custom recombinant antibody and protein production services in CHO cells for biotech and pharmaceutical companies globally, with a 4-week standard turnaround and licensed technology platforms for bispecific, afucosylated, and Fc-silenced formats.
Ownership category
akta.pro rank

evitria industry classification

Industry
Product category
Contract Antibody Production Services
akta.pro industry
PRIMARYHLAMANAE
Exosome & Extracellular Vesicle (EV) Therapeutics
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Recombinant antibody production
  • CHO cell expression services
  • Bispecific antibody manufacturing
  • Therapeutic antibody development
  • Antibody expression CRO

Where evitria is headquartered

Location

Headquarters

HQ city
Zürich
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

evitria business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Custom Antibody Expression Services: evitria provides custom recombinant antibody production services in CHO cells, generating revenue through project-based fees. Services include recombinant IgG production, bispecific antibodies, afucosylated antibodies, Fc-silenced antibodies, high-throughput production, and other recombinant proteins. Pricing is quote-based and depends on antibody format, production scale, timeline, and quality requirements.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goQuote-based pricing tailored to project requirements

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

evitria product offering

Product offering

Core offering

evitria is a CRO providing custom recombinant antibody production services using an optimized CHO (Chinese Hamster Ovary) cell-based transient expression platform. Services span standard IgG production, bispecific and multispecific antibody formats, afucosylated (ADCC-enhanced) antibodies, Fc-silenced antibodies, high-throughput parallel expression, and other recombinant proteins, with a 4-week standard turnaround from sequence to purified protein.

Product overview

evitria is a contract research organization (CRO) providing custom antibody production services using an optimized CHO cell expression platform. The company's portfolio includes six distinct service offerings: Recombinant Antibody Expression Service (standard IgG production), Bispecific Antibody Production Service (dual-targeting formats), Afucosylated Antibody Expression Service (ADCC-enhanced via GlymaxX®), Fc-Silenced Antibody Production Service (reduced effector function via STR technology), High-Throughput Antibody Production Service (parallel expression of hundreds of constructs), and Recombinant Protein Expression Service (non-antibody proteins). These services are powered by three licensed technology platforms: GlymaxX® for glycoengineering, Opti-mAb® for scFv stabilization, and STR for true Fc silencing. All production uses mammalian (CHO) cell-based transient expression with a 4-week standard turnaround.

Differentiator

Problem solved

Functional benefit

Products and services

  • Recombinant Antibody Expression Service Custom production of recombinant monoclonal antibodies in CHO cells, delivering purified proteins from antibody sequences in as little as 4 weeks, with low endotoxin levels (<1 EU/mg). Standard IgG production for biotech and pharma therapeutic programs.
  • Bispecific Antibody Production Service Production of bispecific antibodies capable of simultaneously binding to two different antigens or epitopes. Uses bYlok® technology from Lonza to address heavy-light chain mispairing challenges, with >95% purity achievable.
  • Afucosylated Antibody Expression Service Production of afucosylated antibodies lacking fucose residues in the Fc region, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) for increased therapeutic potency in oncology applications. Uses GlymaxX® glycoengineering technology.
  • Fc-Silenced Antibody Production Service Production of antibodies with reduced or eliminated Fc effector functions using STR (True Fc Silencing) technology from mAbsolve, ideal for neutralizing interactions without triggering immune responses.
  • High-Throughput Antibody Production Service Parallel expression of up to several hundred antibody constructs per project, delivering purified, assay-ready material in as little as 4 weeks with >95% purity. Designed for AI-driven antibody discovery and optimization pipelines.
  • Recombinant Protein Expression Service Production of non-antibody soluble proteins including antigens, extracellular domains, cytokines, viral proteins, and alternative scaffolds using the CHO cell expression platform.

Quantifiable outcome

  • 140,000+ transfections and 25,000+ antibodies delivered since 2010
  • +5 more outcomes

Companies that use evitria

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

evitria technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

evitria partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • AAX BiotechcoreStrategic or Co-development Partner · 1 April 2026Partnership to enable use of Opti-mAb® technology in early antibody development workflows. AAX Biotech develops proprietary technologies including Opti-mAb® supporting antibody-based therapies. The partnership expands access to scFv stabilization technology for bispecific antibody development.
  • LonzacoreTechnology or Integration · 1 May 2024Non-exclusive license agreement for bYlok® technology enabling simple and reliable development of IgG-like bispecific antibodies. Addresses the challenge of correct heavy chain and light chain pairing in bispecific antibody generation for discovery-stage transient expression research.
  • ProBioGencoreTechnology or IntegrationExclusive licensing partnership for GlymaxX® technology enabling modulation of fucosylation in CHO cells. The technology uses a deflecting enzyme to deplete fucose monosaccharides from glycosylation pathways, allowing fine-tuning from complete lack to fully fucosylated variants. Critical for producing ADCC-enhanced afucosylated antibodies.
  • Atlas AntibodiesminorOthersListed as a partnership on evitria's partnerships page. Nature of partnership not detailed in available sources.
  • Integral MolecularminorOthersListed as a partnership on evitria's HTML sitemap. Nature of partnership not detailed in available sources.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

evitria competitors and assessment

Company assessment

Broad incumbents

  • Lonza: Global CDMO offering end-to-end biologics services including mammalian cell expression, stable cell line development, and GMP manufacturing. Direct comparability on transient and stable CHO expression; Lonza also licenses bYlok® to evitria, making it both a partner and broader incumbent.
  • Charles River Laboratories: Global CRO/CDMO with extensive biologics and antibody discovery services. Comparable through its Antibody Discovery & Optimization offerings; Brad Gartland (evitria's BDM) previously held senior commercial roles at Charles River, highlighting operational overlap.
  • WuXi Biologics: Global biologics CDMO offering discovery through GMP manufacturing with extensive mammalian cell expression capacity. Comparable on CHO-based transient and stable expression but at much larger scale across the value chain.
  • Catalent: Global CDMO with biologics capabilities including mammalian cell line development and biopharmaceutical manufacturing. Comparable in the broader biologics services space, particularly for customers needing integrated discovery-to-GMP workflows.

Direct peers

  • GenScript ProBio: Provides custom antibody and protein production services using mammalian (HEK/CHO) expression, including recombinant antibody expression, bispecific antibody production, and high-throughput formats. Directly competes with evitria on CHO-based transient expression for biotech and pharma customers.
  • ProBioGen: Berlin-based CDMO specializing in mammalian cell engineering, cell line development, and viral vectors. Also licenses its GlymaxX® technology to evitria, making it both a core technology partner and a peer offering CHO-based expression services with proprietary glycoengineering capabilities.
  • Absolute Antibody: Recombinant antibody production and engineering services including antibody reformatting, Fc-engineering, and custom expression. Comparable to evitria on recombinant mAb and Fc-engineered antibody services for therapeutic and research customers.
  • Sino Biological: Recombinant antibody and protein production CRO with HEK293 and CHO cell expression, including bispecific and Fc-engineered formats. Directly comparable service portfolio serving global biotech and pharma with custom antibody expression.
  • Creative Biolabs: Custom antibody services including recombinant antibody production, antibody engineering, bispecific antibody development, and Fc-silencing. Direct competitor to evitria across the full antibody expression service stack.

Emerging players

  • mAbsolve: Developer of the STR (True Fc Silencing) technology that evitria licenses. A focused emerging player in Fc-silenced antibody tools, providing complementary technology and direct partnership/peer dynamics with evitria.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

evitria social profiles

Digital presence

evitria financial estimates

Financial estimate

Revenue estimate

Valuation estimate

evitria leadership team

Management profile

Number of profiles

Profiles3 records

evitria funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

evitria M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about evitria

What does evitria do?

evitria is a CRO providing custom recombinant antibody production services using an optimized CHO (Chinese Hamster Ovary) cell-based transient expression platform. Services span standard IgG production, bispecific and multispecific antibody formats, afucosylated (ADCC-enhanced) antibodies, Fc-silenced antibodies, high-throughput parallel expression, and other recombinant proteins, with a 4-week standard turnaround from sequence to purified protein.

Is evitria a public or private company?

evitria is a private company. It is classified as unknown and is currently operating.

When was evitria founded?

evitria was founded in 2010. It employs 11 to 50 people.

Where is evitria based?

evitria is headquartered in Zürich, Switzerland, in the Europe region.

How does evitria make money?

One revenue line is on record: custom Antibody Expression Services.

Who are evitria's main competitors?

Broad incumbents on record are Lonza, Charles River Laboratories, WuXi Biologics and Catalent. Direct peers are GenScript ProBio, ProBioGen, Absolute Antibody, Sino Biological and Creative Biolabs. mAbsolve is listed as an emerging player.

Does evitria have an API?

No public API is recorded for evitria.

What industry is evitria in?

evitria's product category is Contract Antibody Production Services. Its primary akta.pro industry code is HLAMANAE, Exosome & Extracellular Vesicle (EV) Therapeutics, with a secondary code of HLAAAAAF, Bispecific & Multispecific Antibodies.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EuropaWireEvonik Strengthens Biomanufacturing Offering With New Protein Expression Kit | EuropaWireEvonik has partnered with Zurich-based evitria to launch the eviCHO Expression Kit, a ready-to-use transient protein expression kit based on CHO-K1 cells designed for biopharmaceutical research and development. The kit simplifies protein expression workflows, reduces troubleshooting, and supports faster, more consistent production during the early stages of biologics development. The partnership strengthens Evonik's Advance Precision Biosolutions growth field and expands its biomanufacturing solutions portfolio, following its 2025 partnership with InVitria for recombinant human serum albumin.EuropaWireChinese Hamster Ovary cells | EuropaWireEvonik has partnered with Zurich-based evitria to offer the eviCHO Expression Kit, a ready-to-use CHO cell-based transient protein expression kit for biopharmaceutical research and development. The kit aims to simplify workflows and reduce troubleshooting.EuropaWireEvonik Expands Precision Biosolutions Portfolio Through evitria Partnership | EuropaWireEvonik has partnered with Zurich-based evitria to offer the eviCHO Expression Kit, a protein expression kit based on CHO cells for biopharmaceutical research and development. The kit aims to simplify workflows and reduce troubleshooting in biopharmaceutical research.EuropaWireEvonik and evitria Launch Ready-to-Use CHO-Based Protein Expression Kit | EuropaWireEvonik has partnered with Zurich-based evitria to launch the eviCHO Expression Kit, a ready-to-use transient protein expression kit based on Chinese Hamster Ovary (CHO) cells for biopharmaceutical research and development. The kit is designed to simplify workflows, reduce troubleshooting, and support biologics development workflows. The partnership strengthens Evonik's biomanufacturing offering within its Precision Biosolutions portfolio.The Pharma LetterEvonik partners with evitria to accelerate early biologics developmentGermany's speciality chemicals company Evonik has partnered with global antibody expression specialist evitria to launch a ready-to-use transient protein expression kit based on CHO cells for biopharmaceutical research and development. The kit is designed to enable faster, more reliable, and scalable protein production, addressing key challenges in transient protein expression workflows. Through this collaboration, Evonik is expanding access to evitria's expertise while strengthening its own portfolio of precision biosolutions for biopharma customers.news.cision.comAAX Biotech and evitria to expand access to Opti-mAb® technology in early antibody developmentAAX Biotech and evitria announced a partnership to give evitria customers access to AAX's Opti-mAb technology for early antibody development. The technology improves stability of single-chain variable fragments, and evitria may incorporate it into multispecific formats. The partnership aims to expand Opti-mAb use across antibody discovery programs.EvitriaBispecific Antibodies: The New Frontier in TherapeuticsThis article provides a comprehensive educational overview of bispecific antibodies (bsAbs), explaining their engineered dual-targeting mechanism, historical development since the 1960s, and various formats including IgG-like and non-IgG-like structures. The article reviews FDA-approved bispecific antibody therapeutics spanning from blinatumomab (2014) to linvoseltamab (2025) across indications including hematologic malignancies, solid tumors, and other diseases. The content, published by evitria as promotional scientific content, discusses production challenges such as heavy-light chain mispairing and positions the company's CHO cell expression services as a solution for developers navigating bsAb development.EvitriaWhy Antibody Candidates Fail in Early DevelopmentThe article outlines common reasons for early-stage failure in antibody therapeutics development, including poor developability profiles, unfavorable pharmacokinetics, and immunogenicity concerns. It proposes strategies to de-risk these programs, such as robust profiling, engineering for stability, and partnering with specialized contract development and manufacturing organizations (CDMOs). The piece highlights evitria's specific services and technologies designed to address these challenges and improve candidate success rates.EvitriaFast-Tracking Bispecific Antibody Development: What Can Go Wrong?The article examines the risks and challenges associated with accelerating the development of bispecific antibodies, highlighting potential pitfalls in format selection, production, and regulatory compliance. It outlines strategic recommendations for biopharmaceutical developers to balance speed with quality through early design integration and robust expression platforms. The piece also promotes evitria's specialized services and bYlok® technology as solutions for efficient and safe bispecific antibody manufacturing.UnquoteAfinum teams up with SHS on Evitria buyoutAfinum Management and SHS Beteiligungsgesellschaft are buying Swiss biotech Evitria, the fifth platform investment from Afinum's €410m fund. SHS contributed capital from its fifth fund, and founder Markus Hildinger keeps a 30% stake. The company plans US expansion with Luzerner Kantonalbank leverage.